{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:29:57Z","timestamp":1790512197794,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T00:00:00Z","timestamp":1465430400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) continues to be an important complication of hematopoietic stem cell transplantation and solid organ transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, 314 patients who underwent hematopoietic stem cell transplantation between January 2003 and October 2011 were tested serially for <jats:styled-content style=\"fixed-case\">CMV DNA<\/jats:styled-content> by real\u2010time quantitative polymerase chain reaction (<jats:styled-content style=\"fixed-case\">qPCR<\/jats:styled-content>) for 90 days post transplantation. Patients with <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> viremia &gt;3000 genomes\/mL (equivalent to 2520 IU\/mL) received pre\u2010emptive therapy and were compared with previously published data from solid organ transplant (<jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content>) patients monitored and treated in exactly the same way.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After stem cell transplant (<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>), 48% of patients developed at least 1 episode of viremia. The median duration of a viremic episode was 25 days and the peak viral load (<jats:styled-content style=\"fixed-case\">VL<\/jats:styled-content>) was 4784 genomes\/mL whole blood (equivalent to 4019 IU\/mL). The data demonstrated that recipients with positive <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> serostatus were at increased risk of developing viremia, with 0% of donor\u2010negative\/recipient\u2010negative (D\u2212R\u2212), 3.7% of D+R\u2212, 79.5% of D\u2212R+, and 74.2% of D+R+ groups developing viremia over follow\u2010up (adjusted hazard ratio for D+R\u2212 vs. D+R+ group 0.03; 95% confidence interval 0.004, 0.18; <jats:italic>P<\/jats:italic> = 0.0013). In contrast with <jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content> patients, where 58\/74 (78%) D+R\u2212 patients had viremia, a low risk of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection was seen after stem cell transplantation (1\/27; 3.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>As both groups of patients, the previously published <jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content> patients and the present hematopoietic <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> patients, were monitored using the same protocol and <jats:styled-content style=\"fixed-case\">qPCR<\/jats:styled-content> assay with pre\u2010emptive therapy administered at the same <jats:styled-content style=\"fixed-case\">VL<\/jats:styled-content> cutoffs, the distinct differences seen cannot be explained by differences in testing or management and thus emphasize distinct aspects of the natural history of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection post transplant in these 2 patient groups.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12542","type":"journal-article","created":{"date-parts":[[2016,4,10]],"date-time":"2016-04-10T18:12:34Z","timestamp":1460311954000},"page":"405-414","source":"Crossref","is-referenced-by-count":17,"title":["Cytomegalovirus pre\u2010emptive therapy after hematopoietic stem cell transplantation in the era of real\u2010time quantitative PCR: comparison with recipients of solid organ transplants"],"prefix":"10.1111","volume":"18","author":[{"given":"E.","family":"Panagou","sequence":"first","affiliation":[{"name":"Centre for Virology Division of Infection and Immunity UCL Medical School London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Zakout","sequence":"additional","affiliation":[{"name":"Department of Haematology\/Bone Marrow Transplant Unit Royal Free Hampstead NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Keshani","sequence":"additional","affiliation":[{"name":"Department of Haematology\/Bone Marrow Transplant Unit Royal Free Hampstead NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Infection and Population Health UCL Medical School London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Irish","sequence":"additional","affiliation":[{"name":"Centre for Virology Division of Infection and Immunity UCL Medical School London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mackinnon","sequence":"additional","affiliation":[{"name":"Department of Haematology\/Bone Marrow Transplant Unit Royal Free Hampstead NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kottaridis","sequence":"additional","affiliation":[{"name":"Department of Haematology\/Bone Marrow Transplant Unit Royal Free Hampstead NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fielding","sequence":"additional","affiliation":[{"name":"Department of Haematology\/Bone Marrow Transplant Unit Royal Free Hampstead NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.D.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Centre for Virology Division of Infection and Immunity UCL Medical School London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45449"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.3.1142-1148.2004"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02350-3"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2010.11.011"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1159"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.05.015"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04087.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3472"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91835-X"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1695"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/425905"},{"key":"e_1_2_6_13_1","volume-title":"Expert Committee on Biological Standardization: Collaborative Study to Evaluate the Proposed 1st [first] WHO International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)\u2010Based Assays","author":"Fryer JF","year":"2010"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.2.177"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir002"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu364"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/375075"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00625.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.10.023"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.02.008"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92800-5"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1992.tb06479.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/338624"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2043"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12542","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:27:24Z","timestamp":1695569244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/tid.12542"],"URL":"https:\/\/doi.org\/10.1111\/tid.12542","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}